AI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions
Effect of Displaying Predicted Consequences of AI Treatment Recommendations on Clinicians' Fluid and Vasopressor Decisions in Sepsis: A Randomized Crossover Study
When artificial intelligence (AI) recommends a treatment, clinicians must decide whether to follow it. This study tests whether showing the predicted consequences of a recommendation, in addition to the recommendation itself, helps clinicians accept appropriate advice and reject inappropriate advice.
We developed a clinician-anchored counterfactual model that compares the on-duty clinician's intravenous fluid and vasopressor plan with alternative plans for patients with sepsis. It predicts the patient's course under each plan and recommends a change only when the predicted benefit holds across several plausible assumptions about unrecorded factors; otherwise it states that the evidence is insufficient to recommend a change.
About 72 physicians from two hospitals, stratified by seniority, will review 30 retrospective, de-identified ICU decision points from patients with sepsis. In stage 1, each physician independently specifies fluid and vasopressor doses without any AI information. In stage 2, the same cases are reviewed under three conditions assigned by counterbalanced sequences: the case with the on-duty clinician's plan and no AI (B0); B0 plus the AI recommendation (B1); and B1 plus the predicted consequences of the on-duty and recommended plans (B2). The AI recommendation is identical in B1 and B2. Decision quality is assessed against plans made independently by expert intensivists. No patients are enrolled, and participants' decisions do not affect patient care.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Cases. Thirty decision points were selected from retrospective, de-identified ICU records before the experiment. Sampling was stratified so that the set includes AI recommendations to change treatment and to keep the current plan, both appropriate and inappropriate according to the expert reference. Each patient contributes one decision point, and none of the cases were used to develop the AI system.
Expert reference. A panel of intensivists who did not take part in AI development or in the experiment independently specify a fluid and vasopressor plan for every case, without AI output and without knowledge of study conditions. A participant's plan is scored by the number of dose levels by which it lies outside the range of expert plans (0 if within the range), summed over the two drugs. AI recommendations are classified as appropriate or inappropriate by the same rule before participant data are analyzed.
Analysis. Outcomes are analyzed with mixed-effects models with physician and case as crossed random effects. Secondary outcomes are tested in a prespecified order after the primary outcome to control the overall type I error.
Related non-interventional components. A retrospective comparison of clinicians' and the AI's plans and a prospective shadow deployment, in which the system ran on live ICU data without influencing treatment, are reported alongside this experiment but are not part of the randomized comparison.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400016
- Recrutamento
- The First Affiliated Hospital of Chongqing Medical University
-
Contato:
- Muchan Tao
- Número de telefone: +86 18980918483
- E-mail: orchilipairs@gmail.com
-
-
Sichuan
-
Luzhou, Sichuan, China, 646000
- Recrutamento
- The Affiliated Hospital of Southwest Medical University
-
Contato:
- Muchan Tao
- Número de telefone: +86 18980918483
- E-mail: mooochann@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Licensed physicians in critical care, emergency medicine, anaesthesiology, or respiratory medicine.
- Currently treating ICU patients.
- Able to complete the online questionnaire.
Exclusion Criteria:
- Involvement in developing or evaluating the AI system, or in case selection
- Membership of the expert reference panel
- Participation in the pilot survey
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Sequence A
Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version A): cases 1-10 under B0, cases 11-20 under B1, cases 21-30 under B2. |
Participants review the case together with the on-duty clinician's actual intravenous fluid rate and vasopressor dose and submit a final plan. No AI information is shown. This condition controls for the effect of a second review. As B0, plus the AI output: either a recommended dose level for intravenous fluid and for vasopressor, shown with the corresponding dose range, or a statement that the evidence is insufficient to recommend a change. As B1, with identical AI output, plus the model's predicted mean arterial pressure, lactate and urine output over the next 4 hours under the on-duty plan and under the recommended plan, shown as point estimates. |
|
Experimental: Sequence B
Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version B): cases 1-10 under B1, cases 11-20 under B2, cases 21-30 under B0. |
Participants review the case together with the on-duty clinician's actual intravenous fluid rate and vasopressor dose and submit a final plan. No AI information is shown. This condition controls for the effect of a second review. As B0, plus the AI output: either a recommended dose level for intravenous fluid and for vasopressor, shown with the corresponding dose range, or a statement that the evidence is insufficient to recommend a change. As B1, with identical AI output, plus the model's predicted mean arterial pressure, lactate and urine output over the next 4 hours under the on-duty plan and under the recommended plan, shown as point estimates. |
|
Experimental: Sequence C
Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version C): cases 1-10 under B2, cases 11-20 under B0, cases 21-30 under B1. |
Participants review the case together with the on-duty clinician's actual intravenous fluid rate and vasopressor dose and submit a final plan. No AI information is shown. This condition controls for the effect of a second review. As B0, plus the AI output: either a recommended dose level for intravenous fluid and for vasopressor, shown with the corresponding dose range, or a statement that the evidence is insufficient to recommend a change. As B1, with identical AI output, plus the model's predicted mean arterial pressure, lactate and urine output over the next 4 hours under the on-duty plan and under the recommended plan, shown as point estimates. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Distance of final treatment decisions from the range of expert plans, B2 versus B1
Prazo: At completion of the participant's stage-2 review (single online session, approximately 2 hours)
|
For each case, the number of dose levels by which the participant's final fluid and vasopressor plan lies outside the range of plans made independently by the expert panel (0 = within range), summed over the two drugs. Compared between B2 and B1 with a mixed-effects model with physician and case as crossed random effects, adjusted for stage-1 score, block position and sequence. |
At completion of the participant's stage-2 review (single online session, approximately 2 hours)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Discrimination between appropriate and inappropriate AI recommendations, B2 versus B1
Prazo: At completion of the participant's stage-2 review (single online session, approximately 2 hours)
|
Among cases in which the AI recommends changing treatment, acceptance is defined as a final plan equal to the AI-recommended dose level for the changed drug. The outcome is the interaction between condition (B2 vs B1) and recommendation appropriateness (classified by the expert-range rule before analysis) on acceptance, estimated with a mixed-effects probit model with physician and case as crossed random effects. |
At completion of the participant's stage-2 review (single online session, approximately 2 hours)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- KY2026132
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified participant-level responses (treatment decisions, confidence, response times, condition assignments and participant characteristics without identifiers) will be shared. Patient case material derived from source databases will be shared only as permitted by their data use agreements.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .